UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma

Burgos-Panadero, R; El Moukhtari, SH; Noguera, I; Rodríguez-Nogales, C; Martín-Vañó, S; Vicente-Munuera, P; Cañete, A; ... Noguera, R; + view all (2021) Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma. International Journal of Pharmaceutics , 608 , Article 121058. 10.1016/j.ijpharm.2021.121058.

[thumbnail of 1-s2.0-S0378517321008644-main.pdf] Text
1-s2.0-S0378517321008644-main.pdf - Accepted version
Access restricted to UCL open access staff until 29 August 2022.

Download (5MB)

Abstract

Treatment in children with high-risk neuroblastoma remains largely unsuccessful due to the development of metastases and drug resistance. The biological complexity of these tumors and their microenvironment represent one of the many challenges to face. Matrix glycoproteins such as vitronectin act as bridge elements between extracellular matrix and tumor cells and can promote tumor cell spreading. In this study, we established through a clinical cohort and preclinical models that the interaction of vitronectin and its ligands, such as αv integrins, are related to the stiffness of the extracellular matrix in high-risk neuroblastoma. These marked alterations found in the matrix led us to specifically target tumor cells within these altered matrices by employing nanomedicine and combination therapy. Loading the conventional cytotoxic drug etoposide into nanoparticles significantly increased its efficacy in neuroblastoma cells. We noted high synergy between etoposide and cilengitide, a high-affinity cyclic pentapeptide αv integrin antagonist. The results of this study highlight the need to characterize cell-extracellular matrix interactions, to improve patient care in high-risk neuroblastoma.

Type: Article
Title: Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma
DOI: 10.1016/j.ijpharm.2021.121058
Publisher version: https://doi.org/10.1016/j.ijpharm.2021.121058
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Tumor microenvironment; nanomedicine; neuroblastoma; cilengitide; etoposide
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > Lab for Molecular Cell Bio MRC-UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10134278
Downloads since deposit
1Download
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item